Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators.
Feigin A, et al. Among authors: walters ka.
Nat Med. 2024 Feb;30(2):606. doi: 10.1038/s41591-022-02070-0.
Nat Med. 2024.
PMID: 36195687
Free PMC article.
No abstract available.